tbuckley/cabot-search huggingface dataset:
AB1029 Serum 14-3-3ETA is Present in JIA and is not Associated with RF+ Polyarthritis: Table 1
Authors: A. Rosenberg, W.P. Maksymowych, Y. Gui, A. Marotta
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Juvenile Idiopathic Arthritis (JIA) is a collective term used to denote clinically discrete subtypes, which include: Enthesitis-related arthritis, Oligoarthritis, Polyarthritis, Psoriatic arthritis, Systemic arthritis and unclassified arthritis. Polyarthritis is further categorized according to rheumatoid factor (RF) status. The International League of Associations for Rheumatology (ILAR) has devised classification criteria of JIA with specific exclusion criteria and its diagnosis is reliant upon clinical symptoms. While laboratory tests like CBC, CRP, ESR, RF, ANA, and anti-CCP add prognostic value, they have limited utility for diagnosis. Thus, markers that can assist in sub-typing JIA at presentation are imperative as this can influence patient management strategy. <h3>Objectives</h3> 14-3-3η is a joint derived, rheumatoid arthritis (RA) specific marker that informs radiographic damage. The purpose of this study was to examine the expression of 14-3-3η in the sub-types of JIA, and to assess whether a relationship existed between 14-3-3η and RF+ polyarthritis. <h3>Methods</h3> 14-3-3η serum levels were measured in 60 JIA patients as shown in Table 1. One-way ANOVA analysis was used to determine if group differences existed. 14-3-3η positivity was defined using the adult RA diagnostic cut-off of ≥0.19 ng/ml. The Fisher9s Exact test was employed to assess the relationship between RF and 14-3-3η positivity in polyarthritis patients. <h3>Results</h3> ANOVA analysis revealed differences in 14-3-3η serum levels between the groups. Patients with RF positive polyarticular disease had significantly higher serum 14-3-3η levels than the other groups. 14-3-3η positivity analysis revealed that 30% of the oligoarthritis, 53% of RF negative polyarticular, 50% of psoriatic and 57% of patients with systemic arthritis were positive for 14-3-3η. Although there were only four patients in the enthesitis group, none of them were 14-3-3η positive. Fisher9s Exact testing returned no significant association between RF and 14-3-3η positive status (p-value =0.35) indicating that the two markers may uniquely inform patient profiles within subtypes of JIA, especially since 53% of RF negative polyarticular JIA patients had positive 14-3-3η tests. <h3>Conclusions</h3> 14-3-3η is a joint-derived mechanistic marker that up-regulates factors that are involved in joint damage pathogenesis. While RF+ polyarthritis patients had higher 14-3-3η levels, in JIA, 14-3-3η expression has no significant association with RF positivity and may provide insights into biochemical processes that uniquely inform JIA sub-typing. <h3>Disclosure of Interest</h3> A. Rosenberg: None declared, W. Maksymowych Consultant for: Augurex Life Sciences Corp, (Co-inventor of 14-3-3η), Y. Gui Employee of: Augurex Life Sciences Corp, A. Marotta Employee of: Augurex Life Sciences, (Co-inventor of 14-3-3η)
The Gaudí–Colon Connection
Authors: T Pinós, X Xiol
Journal: New England Journal of Medicine (1998)

Figure 1. Antonio Gaudi, a world-famous architect, was a leader of the artistic movement known as modernism, which is based on the use of natural forms. In 1906, he built La Pedrera, one of his most prominent buildings in Barcelona, Spain. The arcades of the upper floor (Panel A), recently restored and opened to the public, are very similar in form to the haustrations of the transverse colon (Panel B) seen on colonoscopy in our daily practice. Colonoscopy was introduced in the 1960s. Was Gaudi a visionary who anticipated, 60 years earlier, the images now shown by modern endoscopy?
P1124 : Primary hepatocellular damage lowers alcohol consumption and suppresses peripheral fat mobilization in ALD patients with genetic variant I148M in PNPLA3
Authors: V. Rausch, T. Peccerella, L. Pawella, K. Lackner, E. Yagmur, F. Stickel, S. Herzig, H.-K. Seitz, T. Longerich, B. Straub, S. Mueller
Journal: Journal of Hepatology (2015)
Dysregulation Of Bcl2 Family Proteins Induced By JAK2V617F Mutation Contributes To The Abnormal Expansion Of Neoplastic Initiating Cells
Authors: Lorena Lobo Figueiredo-Pontes, Robert S Welner, Yuta Mishima, Mihoko Yamamoto, Ann Mullally, Daniel G. Tenen, Susumu Kobayashi
Journal: Blood (2013)
PWE-349 Flexible sigmoidoscopy bowel cancer screening in guernsey: a 3-year report
Authors: CN Catherine
Journal: Gut (2015)

<h3>Introduction</h3> Following the publication of the pilot study on flexible sigmoidoscopy for bowel cancer screening in 2010 by Professor Atkins, Guernsey was the first State in the British Isles to implement bowel cancer screening using this method. The screening programme was introduced following a successfully feasibility pilot study in 2011. <h3>Method</h3> A total of 3,139 invitations were sent out in 2012, 2013 and 2014. The names of prospective paricipants are provied by local GPs. In 2012 and 2013 the programme screened participants aged 60years and in 2014, participants aged 60 and 65years old. Fleet enema is used for bowel preparation. The outcomes measured were: response rate, uptake, adenoma detection rate and participant satisfaction survey in 2014. <h3>Results</h3> 1,909 eligible prospective participants accepted and 1,456 completed screening. The response rate for the individual years was 55%, 67%, and 65% for 2012, 2013 and 2014 respectively with an average of 62%. The uptake for the respective years was 36%, 56% and 56%, with an average of 49%. However, when the uptake was calculated using eligible accepted and the number of participants who completed screening for the three years, this was 66%, 84% and 86% respectively. Out of 1,456 participants who completed screening, 157 adenomas were detected, 51 (32%) of which were high risk. The adenoma detection rate (ADR) for the respective years was 12%, 8%, and 12% with an average ADR of 10.7%. Two cancers were identified in the 2012, none in 2013 and two cancers in the last four months of 2014 when 290 65 year old participants were screened. This older population also had more pathologically advanced adenomas. The 2014 participant satisfaction survey recorded that 91% were satisfied with the service and 91% would recommend the test to others. <h3>Conclusion</h3> In conclusion, the uptake and ADR are comparable with the national average. The uptake of the eligible accepted needs to be audited to assess why these prospective participants did not attend. Participant satisfaction with the screening process is very high. Screening the older age group, although more arduous, the process catches advanced adenomas before they become cancerous and early curable cancers. The programme is preparing to screen two age groups, 60 and 65year olds. <h3>Disclosure of interest</h3> None Declared. <h3>Reference</h3> Atkin WS, <i>et al</i>. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet. 2010;375:1624–1633
Two outbreaks of mumps in children vaccinated with the Rubini strain in Spain indicate low vaccine efficacy
Authors: C Pons, T Pelayo, I Pachon, A Galmes, L González, C Sánchez, F Martinez
Journal: Eurosurveillance (2000)

This paper reports a descriptive study of two outbreaks of mumps in Spanish towns in 1998 and an assessment of the efficacy of the vaccine used. It provides evidence of the low level of protection against the mumps virus that has been observed previously
Psychiatric controversy: man's ethical dimension
Authors: S Arieti
Journal: American Journal of Psychiatry (1975)

Although determinism may permeate human existence, man's moral values raise him above the level of an animal and enable him to direct his own life. The author suggests that psychiatrists should influence the patient to exert his will, make conscious choices, and, above all, assume a sense of responsibility for his own actions. In order to free the patient from whatever conditions hinder his will and to help him make choices, psychiatric treatment must consider man's ethical dimension.
Congenital Adrenal Hyperplasia
Authors: Perrin C. White, Maria I. New, Bo Dupont
Journal: New England Journal of Medicine (1987)

(First of Two Parts)CONGENITAL adrenal hyperplasia results from an inherited defect in any of the five enzymatic steps required to synthesize Cortisol from cholesterol. A defect in a particular step may be manifested clinically, not only because cortisol and other steroid hormones are not synthesized effectively but also because precursor steroids proximal to the blocked step may accumulate and be shunted into other metabolic pathways, particularly that of androgen biosynthesis. For example, in one of the earliest reports (in 1865) of a case of congenital adrenal hyperplasia, de Crecchio described a person who was considered to be a female . . .
Efficacy of lithium-tranylcypromine treatment in refractory depression
Authors: L H Price, D S Charney, G R Heninger
Journal: American Journal of Psychiatry (1985)

Twelve inpatients with major depression refractory to at least two controlled antidepressant trials had tranylcypromine added to ongoing lithium treatment. Eleven patients showed reliable improvement in nurses' depression ratings compared with a prior trial of lithium added to an antidepressant that was not a monoamine oxidase inhibitor (MAOI). Eight patients were blindly judged much or very much improved, and all 12 patients improved sufficiently to be discharged. Preclinical studies of conjointly administered lithium and MAOIs suggest that central serotonergic pathways may mediate this robust clinical effect.
PTH-324 Quality of life outcomes following pelvic exenteration and abdominoperineal resection: a prospective comparison study
Authors: R Radwan, H Jones, R Codd, M Evans, M Davies, D Harris, J Beynon
Journal: Gut (2015)

<h3>Introduction</h3> The literature surrounding quality of life in patients undergoing pelvic exenteration is limited. Furthermore, there remains no similar matched comparisons with patients undergoing abdominoperineal resection. The EORTC QLQ-C30 is a validated cancer specific questionnaire that can be used for patients undergoing rectal cancer resection. Our aim was to evaluate and compare differences in long term quality of life for patients with rectal cancer undergoing both abdominoperineal resection and pelvic exenteration at our institute. <h3>Method</h3> All consecutive patients that had undergone either abdominoperineal resection or pelvic exenteration between January 2011 and December 2012 were included in the study. Patient demographics, tumour characteristics, intra-operative details and postoperative outcomes were collected. Patients were asked to complete the EORTC QLQ-C30 questionnaire at baseline (prior to surgery) and at two weeks post-operatively. Subsequent questionnaires were then requested at 3, 6, 12 and 24 months following operation. <h3>Results</h3> A total of 120 patients were included in the study; 60 patients underwent abdominoperineal resection and 60 patients had pelvic exenteration. This cohort consisted of 62 men and 58 women with a median age of 68 (range 31- 89) years. The majority of functional and symptom scale differences were only noted within the first 2 weeks postoperatively with levels being comparable for both groups from 3 months following surgery. Only financial worries remained considerably higher in patients undergoing exenteration for up to 24 months postoperatively. For overall global health status, a significant difference was again only identified 2 weeks postoperatively (p = 0.032), with those patients undergoing exenteration experiencing a lower overall level. From 3 months following surgery, no further differences were identified. <h3>Conclusion</h3> This is one the largest longitudinal observational studies looking at quality of life in patients undergoing pelvic exenteration and the first to compare these patient outcomes against a matched APER group. Here we have shown that the length of time it takes for these patients to reach a quality of life similar to that of their counterpart APER group is not dissimilar. These data will undoubtedly help counsel patients about recovery times and will guide informed decision making in the future. <h3>Disclosure of interest</h3> None Declared.
CD70/CD27 Signaling Mediates Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors By Compensatory Activation of the Wnt Pathway
Authors: Carsten Riether, Christian M. Schürch, Ramin Radpour, Magdalena Hinterbrandner, Anne-Laure Huguenin, Adrian F. Ochsenbein
Journal: Blood (2014)
Effect of Partial Hepatectomy on Tumor Incidence and Metabolism of Mice Fed Thioacetamide
Authors: P. A. Date, S. V. Gothoskar, S. V. Bhide
Journal: JNCI Journal of the National Cancer Institute (1976)

Six-week-old male Swiss mice were given 0.03% thioacetamide (TAA) in the diet 24, 72, and 168 hours after partial hepatectomy. TAA-treated mice from all three groups were killed when they were 4, 9, and 13 months old. Intact and partially hepatectomized animals on normal diets served as controls. None of the controls evidenced neoplasms at any age. All three experimental groups developed liver tumors earlier than did intact mice treated with the TAA diet. Progressive metabolic studies on the livers or tumor tissues of treated mice showed that the levels of glucose-6-phosphatase, fructose-1,6-diphosphatase, and glycogen decreased significantly in the 4-month-old treated group when there was no significant alteration in liver histology. These parameters were lowest in the tumor tissues of treated mice.
Toward rational pharmacotherapy for posttraumatic stress disorder: an interim report
Authors: M J Friedman
Journal: American Journal of Psychiatry (1988)

There is growing evidence that medication can alleviate symptoms associated with posttraumatic stress disorder (PTSD). Recent research also suggests that PTSD has a unique biological profile consisting of alterations in sympathetic arousal, the neuroendocrine system, and the sleep/dream cycle. This profile distinguishes PTSD from both major depression and panic disorder. Medication appears to alleviate PTSD symptoms associated with sympathetic hyperarousal and intrusive recollections of the trauma but seems ineffective against avoidant symptoms. Pharmacotherapy alone is rarely sufficient to provide complete remission of PTSD. Symptom relief provided by medication facilitates the patient's participation in individual, behavioral, or group psychotherapy.
AB0416 Early Good Eular Response Predicts Low/Remission Disease State in Rheumatoid Arthritis Patients on Treatment with Certolizumab in Real Life Settings. Data from Italian Registry Gisea: Table 1
Authors: F. Iannone, G. Carlino, A. Marchesoni, P. Sarzi-Puttini, R. Gorla, F. Salaffi, R. Foti, G. Ferraccioli, C. Salvarani, E. Fusaro, C. Ferri, G. Paolazzi, G. Lapadula
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Identifying early predictors of sustained clinical response in patients with rheumatoid arthritis (RA) is a major challenge and would have substantial clinical and economic impact. <h3>Objectives</h3> To evaluate the predicting value of a EULAR good clinical response at 3 months to reach Low Disease Activity (LDA)/Remission in RA patients treated with certolizumab in a standard of care setting. <h3>Methods</h3> Patients with RA treated with certolizumab because of their active disease included in the GISEA (Gruppo Italiano Studio Early Arthritis) register were prospectively analysed. The first endpoint of this study was to assess the value of 3 a months good EULAR clinical response to predict a LDA, 28-joints Disease Activity Score (DAS28) ≤3.2 or disease remission (DAS28 &lt;2.6) at 6-12 months. Moreover, the baseline factors that might predict the 3 months EULAR good response therapy were also evaluated. <h3>Results</h3> At entry, 278 patients (female 84%) had active disease (DAS28 5.1±1), age 54.8±12 years, mean duration of disease 9.8±8 years, and BMI 25.5±4 kg/m<sup>2</sup>. Certolizumab was given as first ever biological drug in 68% RA patients, and as ≥2 line biological treatment in 32%. The majority of the patients were also assuming glucocorticoids (77%) and 77% were on co-therapy with Disease Modifying Drugs (DMARDs). At 3 months, DAS28 significantly dropped at 4.01±1 and further decreased at 6 (3.2±1) and 12 (3.3±1) months, respectively (p&lt;0.001). The percentage of patients achieving a good EULAR response was 52.1% at 3 months, 65.2% at 6 months, and 65.9% at 12 months. While patients attaining a state of LDA/disease remission were 51.5% at 6-12 months. The logistic multiple regression analysis (Table 1) showed that 1st line therapy was the only predictor (RR 6.7) of a good EULAR response, after adjustment for age, sex, disease duration, DAS28 at baseline. Furthermore, a good EULAR response at 3 months was the only strong positive predictor (RR 11.3) of LDA/DAS28 disease remission at 6-12 months, while the baseline DAS28 was negatively correlated (RR 0.31). <h3>Conclusions</h3> This study provided evidence that, in the daily standard of care, RA patients on therapy with certolizumab achieving an early good EULAR response by 3 months maintain the good clinical outcome across 6-12 months, and predicts LDA/disease remission at 6-12 months. <h3>Disclosure of Interest</h3> None declared
SAT0421 Random Spot Urine Protein/Creatinine Ratio is a Suboptimal Predictor of 24H Proteinuria in Lupus Nephritis
Authors: R. Fonseca, I. Castro Ferreira, R. Neto, E. Pereira, E. Mariz, M. Pestana, L. Costa
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> The <i>gold standard</i> to assess proteinuria is the protein content of 24h urine collection. Random spot urine protein/creatinine (P/C) ratio seems to have a good correlation with 24h protein and has been used to simplify urine collection. However, it has been reported that it is unreliable for monitoring proteinuria in lupus nephritis (LN) patients. <h3>Objectives</h3> To evaluate the agreement between random spot urine P/C ratio (mg/g) and protein measured by 24h urine collection (g/24h) in LN patients. <h3>Methods</h3> Cross-sectional study was performed. Patients with biopsy proven LN underwent 24h urine collection (for P and C) and random urine (for P/C ratio), sequentially. Correlation (Spearman rank correlation analysis) and limits of agreement between the two methods (Bland-Altman plot analysis) were evaluated. The discriminant cut-off values for spot urine P/C ratio in predicting 24h protein threshold excretion &gt;300, 500, 1000 and 1500 mg were determined using receiver operating characteristics curve (ROC). <h3>Results</h3> Sixty-one paired (total 122) spot and 24h urine collection were evaluated. The mean glomerular filtration rate (assessed by CKD-E equation) was 97mL/min/1.73m<sup>2</sup> (SD 10.9). Strong correlation (r=0.921, p&lt;0.001) was found between the two measures. Stratifying by protein degrees, less strong correlation was found between the two methods (r=0.722, p&lt;0.001 when 24h protein &lt;500mg and r=0.699, p&lt;0,001 when 24h protein was between 500 and 1000 mg). Bland-Altman analysis showed wide limits of agreement (-496.1 to 891.3 mg) and the limits became wider as the protein excretion increased. In low level of protein excretion (&lt;500mg) the two tests had acceptable limits of agreement (-122.3 to 194.7 mg) but in subnephrotic range (500-3400mg), Bland-Altman plot showed clinically inacceptable wide limits of concordance (-438.1 to 1198.8 mg). Using ROC curves, the spot urine P/C ratio discriminant values of 270.3 mg/g (sensitivity (S) 89.2%, specificity (E) 91.7%, area under the curve (AUC) 0.976), 336.5 mg/g (S 93.8%, E 96.6%, AUC 0.990), 655 mg/g (S 87%, E 92.1%, AUC 0.953) and 931 mg/g (S 100%, E 91.7%, AUC 0.958) predicted 24h protein equivalent “thresholds” of &gt;300, 500, 1000 and 1500mg, respectively. <h3>Conclusions</h3> Spot urine P/C ratio and 24h protein have good agreement in low protein levels (&lt;500 mg). In subnephrotic protein range (500-3400), even though we found a good correlation between the two methods, the P/C ratio seems to be a weak predictor of 24h protein showing unacceptable limits of agreement. <h3>Disclosure of Interest</h3> None declared
Studies of Various Tests for Malignant Neoplastic Diseases. VI. Tests for the Least Coagulable Serum Protein and the Iodoacetate Index
Authors: Lester D. Ellerbrook, E. Colton Meek, Stuart W. Lippincott
Journal: JNCI Journal of the National Cancer Institute (1951)

Journal Article Studies of Various Tests for Malignant Neoplastic Diseases. VI. Tests for the Least Coagulable Serum Protein and the Iodoacetate Index Get access Lester D. Ellerbrook, Lester D. Ellerbrook Clinical Trials Unit, Cancer Control Branch, National Cancer Institute, Bethesda, Md. and Department of Pathology, School of Medicine, University of Washington, Seattle, Wash. Search for other works by this author on: Oxford Academic PubMed Google Scholar E. Colton Meek, E. Colton Meek Clinical Trials Unit, Cancer Control Branch, National Cancer Institute, Bethesda, Md. and Department of Pathology, School of Medicine, University of Washington, Seattle, Wash. Search for other works by this author on: Oxford Academic PubMed Google Scholar Stuart W. Lippincott Stuart W. Lippincott Clinical Trials Unit, Cancer Control Branch, National Cancer Institute, Bethesda, Md. and Department of Pathology, School of Medicine, University of Washington, Seattle, Wash. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 12, Issue 1, August 1951, Pages 49–89, https://doi.org/10.1093/jnci/12.1.49 Published: 01 August 1951 Article history Received: 28 March 1951 Published: 01 August 1951
Morphogenesis of Marek's Disease Virus in Feather Follicle Epithelium2
Authors: E. A. Johnson, C. N. Burke, T. N. Fredrickson, R. A. DiCapua
Journal: JNCI Journal of the National Cancer Institute (1975)

Three evaluative systems, immunodiffusion, fluorescent antibody (FA), and electron microscopy (EM), were used to follow the morphogenesis of Marek's disease virus in inoculated chickens. Of the three, EM and FA were the most sensitive in detecting early stages of infection. Virus particles were found in skin biopsy specimens as early as 12 days post inoculation. Immature naked particles appeared first in the nucleus; later particles were enveloped in the cytoplasm and enclosed in cytoplasmic inclusion bodies. No evidence for continued virus replication was seen in feather follicles after an initial burst of heavy virus production, which lasted several weeks. Residual virus, however, was found occasionally in cytoplasmic inclusion bodies within keratinized material near the feathers. This was believed to contribute to the long-term shedding of infectious virus into the environment.